Kamran Zargar-Shoshtari

Kamran Zargar-Shoshtari

Auto-generated profile, based on publicly available information

Kamran Zargar-Shoshtari

Department of Surgery University of Auckland Auckland New Zealand

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in International Journal of Surgery
Verified
Journal Article
Closed access
AKArman Kahokehr
Arman Kahokehr
TSTarik Sammour
Tarik Sammour
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
LTLisa Thompson
Lisa Thompson
AHAndrew G. Hill
Andrew G. Hill
Multimodal care or Enhanced Recovery after Surgery (ERAS) protocols are gaining popularity in order to modify surgical stress responses after colonic resection. However, these protocols are not straightforward to implement as peri-operative care is varied. We aimed to identify areas that may need attention in order to successfully change practice. The literature was reviewed for current practice, methods and issues in implementing ERAS. Based on this and our own experience we discuss several important areas that need particular attention in developing and sustaining an ERAS program. International surveys have shown that current peri-operative care in colorectal resection is not evidence based. Important aspects of the ERAS philosophy including patient counselling, teamwork and attitude change are identified and discussed. Implementing evidence-based peri-operative care into practice is challenging. Barriers to multimodal recovery pathways should be addressed.

1 January 2016 in European Urology
Verified
Journal Article
Closed access
HZHomayoun Zargar
Homayoun Zargar
TAThomas D. Atwell
Thomas D. Atwell
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu
JRJean J. de la Rosette
Jean J. de la Rosette
GJGunther Janetschek
Gunther Janetschek
RTR. Houston Thompson
R. Houston Thompson

1 August 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
PSPranav Sharma
Pranav Sharma
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
JCJamie T. Caracciolo
Jamie T. Caracciolo
MFMayer Fishman
Mayer Fishman
MPMichael A. Poch
Michael A. Poch
Philippe SpiessPhilippe Spiess
Philippe Spiess

1 January 2016 in Journal of Urology
Verified
Journal Article
Closed access
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
HZHomayoun Zargar
Homayoun Zargar
YLYair Lotan
Yair Lotan
JSJay B. Shah
Jay B. Shah
BRBas W. van Rhijn
Bas W. van Rhijn
LFLaura S. Mertens Collaborators Adrian S. Fairey
Laura S. Mertens Collaborators Adrian S. Fairey
Selected patients with bladder cancer with pelvic lymphadenopathy (cN1-3) are treated with induction chemotherapy followed by radical cystectomy. However, the data on clinical outcomes in these patients are limited. In this study we assess pathological and survival outcomes in patients with cN1-3 disease treated with induction chemotherapy and radical cystectomy. Data were collected on patients from 19 North American and European centers with cT1-4aN1-N3 urothelial carcinoma who received chemotherapy followed by radical cystectomy between 2000 and 2013. The primary end points were pathological complete (pT0N0) and partial (pT1N0 or less) response rates, with overall survival as a secondary end point. Logistic regression and Cox proportional hazard ratios were used for multivariate analysis of factors predicting these outcomes. The total of 304 patients had clinical evidence of lymph node involvement (cN1-N3). Methotrexate/vinblastine/doxorubicin/cisplatin was used in 128 (42%), gemcitabine/cisplatin in 132 (43%) and other regimens in 44 (15%) patients. The pN0 rate was 48% (cN1-56%, cN2-39%, cN3-39%, p=0.03). The complete and partial pathological response rates for the entire cohort were 14.5% and 27%, respectively. The estimated median overall survival time for the cohort was 22 months (IQR 8.0, 54). On Cox regression analysis overall survival was associated with pN0, negative surgical margins, removal of 15 or more pelvic nodes and cisplatin therapy. Complete pathological nodal response can be achieved in a proportion of patients with cN1-3 disease receiving induction chemotherapy. The best survival outcomes are observed in male patients on cisplatin regimens with subsequent negative radical cystectomy margins and complete nodal response (pN0) with excision of 15 or more pelvic nodes.

1 November 2015 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
PSPranav Sharma
Pranav Sharma
RDRosa Djajadiningrat
Rosa Djajadiningrat
KZKamran Zargar-Shoshtari
Kamran Zargar-Shoshtari
MCMario Catanzaro
Mario Catanzaro
YZYao Zhu
Yao Zhu
Philippe SpiessPhilippe Spiess
Philippe Spiess

3 February 2009 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KZKamran Zargar‐Shoshtari
Kamran Zargar‐Shoshtari
AHAndrew G. Hill
Andrew G. Hill